For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Named Technology Group of the Year by Law360
  • Ranked #1 in the Americas for number of technology deals in 2015 by Mergermarket
  • Nearly 20 percent of Fenwick partners are ranked by Chambers
  • Consistently ranked among the top 10 law firms in the U.S. for diversity
  • Recognized as having top mentoring and pro bono programs by Euromoney


We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041

San Francisco Office
555 California Street
13th Floor
San Francisco, CA 94104

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101

New York Office
1211 Avenue of the Americas
32nd Floor
New York, NY 10036

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200

Daniel M. Becker, M.D.

Partner, Intellectual Property  

Mountain View 650.335.7970


​Daniel Becker represents pharmaceutical and biotechnology companies in all areas of patent counseling, including life cycle management, post-issuance proceedings, patent portfolio development and restructuring, peer review of patent portfolios, transactional and financing IP due diligence, and offensive and defensive patent strategy. He is a registered patent lawyer.

Dan has extensive experience in pharmaceutical life cycle management, both for marketed pharmaceutical products and for products in late-stage clinical development that require additional patent term. Prior to joining Fenwick, Dan had been responsible for worldwide prosecution of a second generation patent family protecting one of the world's best-selling prescription pharmaceuticals. For an Italian specialty pharmaceutical company with an NDA pending at the FDA, Dan secured issuance of two next-generation patents covering the proposed clinical indication for the company's new chemical entity for treatment of Parkinson's disease, for which first generation composition of matter claims had already expired. For a venture-backed company repurposing a drug product that had earlier failed clinical trials in a different indication, Dan designed a strategy for newly claiming the drug substance per se, including advice on new in vitro experiments, and drafting, filing and prosecution of a new patent application, achieving allowance of Orange Book-listable claims shortly after acquisition of the company in 2013. In 2012, in an effort to secure additional patent term for a newly-issued patent covering a French client's lead compound, Dan argued cross-motions for summary judgment in the District Court for the Eastern District of Virginia, advancing a patent term adjustment theory crafted in collaboration with a former colleague.

In his post-issuance practice, Dan has represented clients before the USPTO's Patent Trial and Appeal Board in interference proceedings and on appeal from ex parte reexamination and inter partes reexamination. He has served as lead counsel in 10 concurrent ex part​e and inter partes reexamination proceedings in the past few years, including reexamination concurrent with infringement litigation.

Dan also provides peer review of patent portfolios, typically in advance of major financings or strategic exit.

Prior to joining Fenwick & West, Dan was a partner in the Intellectual Property and Life Sciences practices of a large general practice firm. Dan has served as a patent advisor to Nature Reviews Drug Discovery, published by the Nature Publishing Group.

For each of the last seven years, Chambers USA has recognized Dan as a leading lawyer, nationwide, in the area of Life Sciences: IP/Patent Litigation. According to Chambers USA 2015, he is recommended by his clients for his ability to take a “broader commercial view” when counseling his clients on all aspects of portfolio management. In 2016, Legal 500 (US) recommended Dan in two separate categories, Venture Capital & Emerging Companies and Patents: portfolio management and licensing. In the 2015 and 2013 editions of Legal 500 (US) Dan was recommended for patent licensing and transactions. Since 2012, Dr. Becker has been identified as a “Life Science Star” in LMG Life Sciences and its predecessor publication, Expert Guide to Life Science Attorneys.

Prior to his legal career, Dan conducted research in molecular immunology and in mammalian gene expression.